BioWorld

Dec. 4, 2008

OncoGenex Gains 75 Percent on OGX-011 Phase II Prostate Data

Shares of OncoGenex Pharmaceuticals Inc. soared 75.6 percent on Wednesday thanks to positive survival data from a Phase II trial of lead compound OGX-011 in the first-line treatment of hormone refractory prostate cancer (HRPC). (BioWorld Today) Read More

Catalyst Advancing Hemophilia Drug with $40M Series C Round

In Time for the Holidays, Targets Identified for Battle of the Bulge

Genta's Genasense Rejected Again by the FDA for CLL

Pozen Drug Meets Endpoints, but FDA Decision Awaited

With GVAX Failures,Takeda to End Partnership with Cell Genesys

Appointments And Advancements

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 5, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 2, 2026

Janssen Pharmaceutica reports new TMEM175 activators

BioWorld Science

Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...

Cancer specter looming, Abtect effect in UC wallops Abivax

BioWorld

Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...

FB-7033 demonstrates efficacy in MASH management

BioWorld Science

17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...